Ledger.Open graph →
SEC Form D · filed February 14, 2024

NextPoint Therapeutics, Inc

Offering
$42.5M
Sold
$42.5M
Exemption
Rule 506(b)
Industry
Biotechnology
Location
CAMBRIDGE, MA
Type

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (20)

Paulina Hill · Cambridge, MADirectorPaul Conrad · Cambridge, MAExecDetlev Biniszkiewicz · Cambridge, MADirectorRakhshita Dhar · Cambridge, MADirectorDouglas W. Brown · Cary, NCExecRenan Ugalde Amezcua · RALEIGH, NCDirectorDental Innovation Alliance Management Company, LP · Cary, NCDirectorThomas A. Sharpe · Cary, NCDirectorMatthew Roden) · Cambridge, MADirectorAxel Hoos · Cambridge, MADirectorIvan Cheung · Cambridge, MAExec · DirectorR. Jacob Vogelstein · Bethesda, MDDirectorBonBillo Ventures Manager II LLC · North Easton, MADirectorJan Hermesdorf · Luxembourg, LuxembourgDirectorSteven J. Greenblatt · New York, NYExecThomas O'Neill · Somerset, NJDirectorMatthew Roden) · Cambridge, MADirectorAxel Hoos · Cambridge, MADirectorIvan Cheung · Cambridge, MAExec · DirectorR. Jacob Vogelstein · Bethesda, MDDirector

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗